Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1741 to 1755 of 8213 results

  1. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    Awaiting development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Satralizumab for treating thyroid eye disease [ID6648]

    Awaiting development Reference number: GID-TA11860 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]

    Awaiting development Reference number: GID-TA11861 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

    Awaiting development Reference number: GID-TA11626 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Omental lymph node transfer for lymphoedema of the limbs

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  6. Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]

    In development Reference number: GID-TA11140 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    In development Reference number: GID-TA11342 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Eneboparatide for treating chronic hypoparathyroidism [ID6532]

    In development Reference number: GID-TA11688 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Dupilumab for treating bullous pemphigoid [ID6479]

    In development Reference number: GID-TA11615 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]

    In development Reference number: GID-TA11747 Expected publication date:  14 April 2027

    Technology appraisal guidance
    In development

  11. Male sling for stress urinary incontinence

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  12. Capsule sponge tests for surveillance of Barrett's oesophagus (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

    Health technology evaluations
    In development

  13. Asunercept for treating glioblastoma [1301]

    In development Reference number: GID-TA10227 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

    In development Reference number: GID-TA10623 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Technologies to improve detection of endometrial cancer

    Awaiting development Reference number: GID-HTE10083 Expected publication date: TBC

    Health technology evaluations
    Awaiting development